NCT00313001View on ClinicalTrials.gov

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

PHASE3CompletedINTERVENTIONAL
Enrollment

373

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

DRUG

exenatide

Trial Locations (1)

08536

Novo Nordisk Investigational Site, Plainsboro

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY